Literature DB >> 28902277

Clinical manifestations of chikungunya among university professors and staff in Santo Domingo, the Dominican Republic.

Michael A Zingman1, Amarilis Then Paulino2, Matilde Peguero Payano2.   

Abstract

OBJECTIVE: To further characterize chikungunya virus infection and its associated clinical manifestations, using a sample of university professors and staff in Santo Domingo, the Dominican Republic.
METHODS: A cross-sectional study with quota sampling by department was performed to obtain a convenience sample of professors (n = 736) and staff (n = 499) at the Universidad Autónoma de Santo Domingo. Surveys were used to collect demographic and infection data during the fall term of 2014. Univariate and bivariate analyses were carried out to quantify infection and clinical manifestation prevalence and to assess relationships of these outcomes with age, sex, and acute phase duration.
RESULTS: Of 1 236 participants, 49% reported infection (professors = 41%; staff = 61%). Of these, 53% also reported the presence of chronic effects, largely arthralgia (48%). Significant relationships were observed between reported infection and sex (P = 0.023), age (P < 0.001), and occupation (P < 0.001). More headache (P = 0.008) and edema (P < 0.001) in females, more headache (P = 0.005) in younger subjects, and more myalgia (P = 0.006) in those with longer acute symptoms were found. Additionally, more chronic arthralgia (P < 0.001; P = 0.003) and chronic edema (P < 0.001; P = 0.001) in females and older subjects, and more chronic myalgia (P = 0.041) and chronic edema (P = 0.037) in those with longer acute symptoms were observed.
CONCLUSIONS: To the authors knowledge, this is the first population-based chikungunya prevalence study in the Dominican Republic, and the first to explore clinical manifestations in a university setting. The findings reflect results from studies following the 2005 - 2006 Reunion Island outbreak: prevalence of infection and chronic arthralgia, as well as associations with sex, age, and acute intensity. Longitudinal research can provide further insight into these effects.

Entities:  

Mesh:

Year:  2017        PMID: 28902277      PMCID: PMC6612746     

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


Chikungunya (CHIK) is a vector-borne disease caused by infection with the chikungunya virus (CHIKV), a ribonucleic acid (RNA) arbovirus from the family Togaviridae and genus Alphavirus (1, 2). Transmission occurs through two mosquito species, Aedes aegypti and Aedes albopictus (3, 4). The virus was initially isolated in Tanzania in 1952 and named “chikungunya” after the Makonde word meaning “that which bends up,” referring to symptoms experienced by affected individuals (5). Infection has occurred mainly in periodic outbreaks in Africa and Asia. In 2006, there were two major epidemics with high attack rates, including over 1 million cases in India and approximately 300 000 cases in Reunion Island, a French territory in the Indian Ocean (3, 6). In December 2013, however, cases of CHIKV infection on the Caribbean island of St. Martin triggered the Pan American Health Organization (PAHO) to release the first alert about CHIKV in the Region of the Americas (2, 7, 8). Since then, local transmission has been confirmed in 43 countries and territories of the Region, with over 1.3 million suspected cases (2). In February 2014, cases of a febrile syndrome accompanied by arthralgia were reported in the town of San Gregorio de Nigua in the San Cristóbal province of the Dominican Republic. This town is adjacent to a large commercial port that receives daily imports from overseas. These cases, confirmed to be CHIKV infection by the United States Centers for Disease Control and Prevention (CDC; Atlanta, Georgia, United States) in April 2014, marked the beginning of an epidemic in the Dominican Republic. Over 530 000 suspected cases were reported in the Dominican Republic from 2013 – 2014 (7, 9). In 2015, however, newly suspected cases dropped to just 67 (7), a clear decline from the recent peak of the epidemic. Due to the cyclic nature of epidemics and the inability to be re-infected with CHIKV, it is not yet clear if the virus will remain endemic in the country. Therefore, monitoring and surveillance remain crucial, as well as ongoing evaluation of the infestation indexes of Aedes mosquitoes (4, 9, 10). According to the national CHIKV preparation and response plan (11), the first entomological studies showed a house index of 0.2 – 2.5 and elevated infestation in water containers used for household consumption. Prior to symptom onset, CHIKV has both an “extrinsic incubation period” in which it replicates in the salivary glands of the mosquito (average 10 days) and an “intrinsic incubation period” in the human host following the mosquito bite (average 3 – 4 days; range = 2 – 10 days) (3). In the acute phase, symptoms often begin abruptly with high fever and arthralgia (3, 12). In severe cases, joint inflammation can lead to swelling, redness, and limited movement, necessitating rest and absence from daily activities. Initial effects last approximately 3 – 10 days and can also be accompanied by, but not limited to: headache, myalgia, edema, nausea, vomiting, chills, and conjunctivitis (3). In the majority of cases, the acute phase duration is 2 – 5 days (13). After a sub-acute or convalescent phase of up to 12 weeks in which there is no viremia, chronic effects often follow. Common chronic manifestations include degenerative disc disease, arthritis, depression, anxiety or panic disorders, and visual impairment (14). Continued inflammation can lead to recurrence of arthralgia in affected joints (15, 16). The chronic pain after CHIKV infection can be greater than during the acute disease, resulting in a significant burden on quality of life (17). These effects have been shown to continue for up to 5 years (18). In two studies from Reunion Island, 60% – 63% of patients had persistent arthralgia 1.5 – 3 years after the epidemic, with about half reporting a negative impact on quality of life (17, 19). Several common risk factors for chronic arthralgia have been highlighted, including age > 45 years, intensity of acute pain, and past medical history of arthralgia (20–22). Much of the current literature has focused on describing barriers and improvements to treatment, control, surveillance, and prevention of CHIKV infection in the Americas (3, 4, 9, 10), but is insufficient in highlighting the impact of infection on specific populations. This paper will attempt to further characterize the recent epidemic in the Dominican Republic and the clinical manifestations of CHIKV infection by observing the specific impact on personnel at the Universidad Autónoma de Santo Domingo (Autonomous University of Santo Domingo; Santo Domingo, Dominican Republic UASD). Additionally, it will look at particular factors related to prevalence of clinical symptoms, with an emphasis on chronic effects. Learning more about the behavior of these manifestations may help the medical and public health communities to better develop CHIKV prevention and treatment strategies for the Americas and limit the burden of the chronic phase of infection.

MATERIALS AND METHODS

A descriptive cross-sectional study was conducted to observe the prevalence, impact, and clinical manifestations of CHIKV infection among professors and staff in a university setting following the outbreak in 2014. The Institutional Review Board at Columbia University Medical Center (New York City, New York, United States) approved all study protocols. Prior to participation, all subjects were informed of the study objectives and scope, and assured that withdrawal would be permitted at any time. All participants provided informed consent prior to the interviews; data were anonymous and confidential.

Study setting

All research was carried out at UASD, the largest and only public university in the Dominican Republic. Surveys were completed through interviews performed by researchers and students on the main campus in Santo Domingo during the fall term of 2014. Analysis was performed at the Office of Health Sciences Research during the summer term of 2015.

Sample size and sampling procedure

Two separate sample sizes (professors and staff) were used. The university staff population was 3 348 and the professor population was 2 969. The appropriate probabilistic sample size was calculated using Epi Info™ version 7.1.3 (CDC, Atlanta, Georgia, United States), separately for each group (professors and staff), based on a 95% Confidence Interval (95%CI), 50% expected prevalence (20, 23–29), and 2% design effect. The sample size calculated (plus an additional 10%) was 693 for staff and 748 for professors. Using a quota sampling method by school (professors) or department (staff), selections were made by convenience depending on presence in classrooms, offices, and recreational rooms. In all, the study sample comprised 499 staff and 736 professors.

Data collection

The interviewers presented themselves to the professors and staff, and described in detail the study’s aims, risks, and benefits, in addition to its informed consent process. Subjects who agreed to participate signed consent forms. Interviews proceeded and survey forms were completed for each participant. Two separate anonymous survey forms were used for data collection, one per group, and later combined for analysis. The information collected was the same for both surveys. Data collection took place over a 2-month period. The surveys were composed of 14 closed- and open-ended questions that collected general data such as age, sex, school, and department, as well as information related to CHIKV infection: clinical manifestations, acute phase duration, diagnosis, treatment, and medical attention. The inclusion criteria were: professors and staff who were active at the time of the survey, were present in the work place when surveys were distributed, and had voluntarily accepted participation in the interviews.

Data management and analysis

Data were entered into a combined database in Microsoft Excel™ (Microsoft Corp., Redmond, Washington, United States), and statistical analyses were carried out using STATA® version 13 (Stata Corp LP, College Station, Texas, United States). Univariate analyses were performed to observe the variable distribution and to quantify both acute and chronic manifestations from suspected CHIKV infection. Bivariate analyses were performed to explore the potential relationships between CHIKV infection and exposure variables such as age, sex, and length of the acute phase. Separate and combined analyses for professors and staff were performed. Analysis was primarily focused on descriptive statistics and frequency tables, with chi-squared tests performed to assess significance. Due to the cross-sectional nature of the study, prevalence ratios (PR) were used as the effect measure of interest. Age was converted into a three-level categorical variable and acute phase duration was dichotomized around a cut-off point of 9 days. For outcome variables, reported CHIKV infection and clinical manifestations were considered, all of which were binary based on presence. The study specifically investigated arthralgia, headache, myalgia, and edema as these were the most commonly reported chronic effects. The proportion distribution of each effect in the acute and chronic phases was reported.

RESULTS

The total study population was 1 235 individuals, of which 736 were professors and 499 staff. Of the total, 57% were male, or more specifically, 63% of professors and 47% of staff. The age range was 18 – 84 years (mean 45; standard deviation [SD] = 12.1); among professors, 24 – 84 years (mean 50; SD = 9.8) and staff, 18 – 78 years (mean 38; SD = 11.9) (Table 1).
TABLE 1.

Demographic characteristics of professors and staff surveyed in a study of chikungunya at a university in Santo Domingo, Dominican Republic, 2014

Variable

Total (n = 1 235)

Professors (n = 736)

Staff (n = 499)

No.

%

No.

%

No.

%

Sex

 

 

 

 

 

 

  Female

531

43.00

269

36.55

262

52.51

  Male

704

57.00

467

63.45

237

47.49

Age

 

 

 

 

 

 

  Mean, standard deviation

45.26

12.13

49.99

9.82

38.33

11.87

Age category

 

 

 

 

 

 

  < 36 years

281

22.85

  42

5.75

239

47.90

  36 – 50 years

507

41.22

328

44.87

179

35.87

  > 50 years

442

35.93

361

49.38

  81

16.23

Prepared by the authors using study data.

Variable Total (n = 1 235) Professors (n = 736) Staff (n = 499) No. % No. % No. % Sex Female 531 43.00 269 36.55 262 52.51 Male 704 57.00 467 63.45 237 47.49 Age Mean, standard deviation 45.26 12.13 49.99 9.82 38.33 11.87 Age category < 36 years 281 22.85 42 5.75 239 47.90 36 – 50 years 507 41.22 328 44.87 179 35.87 > 50 years 442 35.93 361 49.38 81 16.23 Prepared by the authors using study data. Among those reporting suspected CHIKV infection, 54% were male, or more specifically 60% of professors and 48% of staff. This group was 18 – 78 years of age (mean 44; SD = 12.3), with professors having a higher median age of 50 years (SD = 9.6) and staff having a lower median age of 38 years (SD = 11.7). In participants reporting suspected CHIKV infection, 38% were diagnosed by a doctor. Staff reported a higher proportion of diagnoses by a doctor than professors, 50% and 27%, respectively (Table 2).
TABLE 2.

Demographic characteristics and outcomes of chikungunya virus infection among professors and staff reporting infection at a university in the Dominican Republic, 2014

Variable

Both (n = 610)

Professors (n = 304)

Staff (n = 306)

No.

%

No.

%

No.

%

Sex

 

 

 

 

 

 

  Female

282

46.23

123

40.46

159

51.96

  Male

328

53.77

181

59.54

147

48.04

Age

 

 

 

 

 

 

  Mean, standard deviation

44.25

12.29

50.38

9.61

38.19

11.65

Age category

 

 

 

 

 

 

  < 36 years

167

27.42

18

5.94

149

48.69

  36 – 50 years

237

38.92

128

42.24

109

35.62

  > 50 years

205

33.66

157

51.82

48

15.69

Diagnosed by

 

 

 

 

 

 

  Self

358

58.69

207

68.09

151

49.35

  Doctor

234

38.36

82

26.97

152

49.67

  Neighbor/other

12

1.97

10

3.29

2

0.65

Acute effects

 

 

 

 

 

 

  Arthralgia

567

92.95

275

90.46

292

95.42

  Fever

561

91.97

278

91.45

283

92.48

  Myalgia

466

76.39

196

64.47

270

88.24

  Headache

415

68.03

178

58.55

237

77.45

  Rash

362

59.34

154

50.66

208

67.97

  Chills

269

44.10

110

36.18

159

51.96

  Edema

236

38.69

106

34.87

129

42.16

  Retroocular pain

176

28.85

53

17.43

123

40.20

  Nausea

136

22.30

39

12.83

97

31.70

  Abdominal pain

110

18.03

33

10.86

77

25.16

  Bloodshot eyes

81

13.28

25

8.22

56

18.30

  Vomiting

61

10.00

16

5.26

45

14.71

Length of time

 

 

 

 

 

 

  < 9 days

450

73.77

221

72.70

229

74.84

  ≥ 9 days

160

26.23

83

27.30

77

25.16

Chronic effects

 

 

 

 

 

 

  Arthralgia

293

48.03

139

45.72

154

50.33

  Edema

49

8.03

34

11.18

15

4.90

  Myalgia

40

6.56

15

4.93

25

8.17

  Headache

18

2.95

5

1.64

13

4.25

  Abdominal pain

11

1.80

4

1.32

7

2.29

  Retroocular pain

7

1.15

4

1.32

3

0.98

  Fever

6

0.98

4

1.32

2

0.65

  Rash

6

0.98

5

1.64

1

0.33

  Bloodshot eyes

4

0.66

4

1.32

0

0.00

  Nausea

3

0.49

3

0.99

0

0.00

  Chills

3

0.49

2

0.66

1

0.33

  Vomiting

1

0.16

1

0.33

0

0.00

: Prepared by the authors using study data.

Variable Both (n = 610) Professors (n = 304) Staff (n = 306) No. % No. % No. % Sex Female 282 46.23 123 40.46 159 51.96 Male 328 53.77 181 59.54 147 48.04 Age Mean, standard deviation 44.25 12.29 50.38 9.61 38.19 11.65 Age category < 36 years 167 27.42 18 5.94 149 48.69 36 – 50 years 237 38.92 128 42.24 109 35.62 > 50 years 205 33.66 157 51.82 48 15.69 Diagnosed by Self 358 58.69 207 68.09 151 49.35 Doctor 234 38.36 82 26.97 152 49.67 Neighbor/other 12 1.97 10 3.29 2 0.65 Acute effects Arthralgia 567 92.95 275 90.46 292 95.42 Fever 561 91.97 278 91.45 283 92.48 Myalgia 466 76.39 196 64.47 270 88.24 Headache 415 68.03 178 58.55 237 77.45 Rash 362 59.34 154 50.66 208 67.97 Chills 269 44.10 110 36.18 159 51.96 Edema 236 38.69 106 34.87 129 42.16 Retroocular pain 176 28.85 53 17.43 123 40.20 Nausea 136 22.30 39 12.83 97 31.70 Abdominal pain 110 18.03 33 10.86 77 25.16 Bloodshot eyes 81 13.28 25 8.22 56 18.30 Vomiting 61 10.00 16 5.26 45 14.71 Length of time < 9 days 450 73.77 221 72.70 229 74.84 ≥ 9 days 160 26.23 83 27.30 77 25.16 Chronic effects Arthralgia 293 48.03 139 45.72 154 50.33 Edema 49 8.03 34 11.18 15 4.90 Myalgia 40 6.56 15 4.93 25 8.17 Headache 18 2.95 5 1.64 13 4.25 Abdominal pain 11 1.80 4 1.32 7 2.29 Retroocular pain 7 1.15 4 1.32 3 0.98 Fever 6 0.98 4 1.32 2 0.65 Rash 6 0.98 5 1.64 1 0.33 Bloodshot eyes 4 0.66 4 1.32 0 0.00 Nausea 3 0.49 3 0.99 0 0.00 Chills 3 0.49 2 0.66 1 0.33 Vomiting 1 0.16 1 0.33 0 0.00 : Prepared by the authors using study data. Of those who completed the survey, 610 (49%) reported suspected infection, including 304 (41%) professors and 306 (61%) staff. The proportion of staff that reported suspected infection by CHIKV was greater than that of professors, and this was statistically significant (P < 0.001). It was also observed that the proportion in females was significantly higher than in males, 53% and 47%, respectively (P = 0.023). Furthermore, the proportion of younger subjects (< 36 years of age) with CHIKV infection was significantly higher than that of older subjects (> 50 years of age) at 60% versus 46%, respectively (P < 0.001) (Table 3).
TABLE 3.

Proportion of reported CHIKV infection by group, sex, and age category in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

Variable

Infection (n = 610)

No infection (n = 623)

P

No.

%

No.

%

Overall (n = 1 235)

610

49.39

623

50.45

 

Staff (n = 499)

306

61.32

191

38.28

< 0.001

Professors (n = 736)

304

41.30

432

58.70

 

Sex

 

 

 

 

 

Female (n = 531)

282

53.11

248

46.70

0.023

Male (n = 704)

328

46.59

375

53.27

 

Age category

 

 

 

 

 

< 36 years (n = 280)

167

59.64

113

40.36

0.001

36 – 50 years (n = 506)

237

46.84

269

53.16

 

> 50 years (n = 442)

205

46.38

237

53.62

 

Prepared by the authors using study data.

Variable Infection (n = 610) No infection (n = 623) P No. % No. % Overall (n = 1 235) 610 49.39 623 50.45 Staff (n = 499) 306 61.32 191 38.28 < 0.001 Professors (n = 736) 304 41.30 432 58.70 Sex Female (n = 531) 282 53.11 248 46.70 0.023 Male (n = 704) 328 46.59 375 53.27 Age category < 36 years (n = 280) 167 59.64 113 40.36 0.001 36 – 50 years (n = 506) 237 46.84 269 53.16 > 50 years (n = 442) 205 46.38 237 53.62 Prepared by the authors using study data. The acute phase duration was reported to be less than 9 days in 74% of participants. The clinical manifestations most reported in the acute phase were (in decreasing order): arthralgia (93%), fever (92%), myalgia (76%), headache (68%), and rash (59%). Staff reported a higher proportion of all of these effects than professors. 53% of participants reported that at least one effect endured past the acute phase (not shown). The manifestations most reported in the chronic phase were (in decreasing order): arthralgia (48%), edema (8%), myalgia (7%), headache (3%) and abdominal pain (2%) (Table 2). Among the reported acute effects, females were significantly more likely than males to report headache (P = 0.008) and edema (P < 0.001). A significant relationship between younger age and reported headache (P = 0.005) was observed, with a higher proportion in those less than 36 years and 36 – 50 years of age, than among those more than 50 years of age. Further, the authors observed that a longer acute phase duration (9 days or greater) was significantly associated with reported myalgia (P = 0.006) (Table 4a).
TABLE 4a.

Proportion distribution of acute manifestations by sex, age, and acute phase length in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

Variable

Acute

Arthralgia

P

Headache

P

Myalgia

P

Edema

P

Yes

No

Yes

No

Yes

No

Yes

No

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

Total (n = 610)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Female (n = 282)

267

94.68

15

5.32

0.122

207

73.40

75

26.60

0.008

214

75.89

68

24.11

0.785

141

50.00

141

50.00

< 0.001

Male (n = 328)

300

91.46

28

8.54

 

208

63.41

120

36.59

 

252

76.83

76

23.17

 

94

28.66

234

71.34

 

> 50 years (n = 205)

188

91.71

17

8.29

0.696

126

61.46

79

38.54

0.005

154

75.12

51

24.88

0.301

90

43.90

115

56.10

0.146

36 – 50 years (n = 237)

222

93.67

15

6.33

 

160

67.51

77

32.49

 

177

74.68

60

25.32

 

87

36.71

150

63.29

 

< 36 years (n = 167)

156

93.41

11

6.59

 

129

77.25

38

22.75

 

135

80.84

32

19.16

 

58

34.73

109

65.27

 

≥ 9 days (n = 160)

145

90.63

15

9.37

0.181

110

68.75

50

31.25

0.821

135

84.38

25

15.62

0.006

72

45.00

88

55.00

0.050

< 9 days (n = 450)

422

93.78

28

6.22

 

305

67.78

145

32.22

 

331

73.56

119

26.44

 

163

36.22

287

63.78

 

Variable Acute Arthralgia P Headache P Myalgia P Edema P Yes No Yes No Yes No Yes No No. % No. % No. % No. % No. % No. % No. % No. % Total (n = 610) Female (n = 282) 267 94.68 15 5.32 0.122 207 73.40 75 26.60 0.008 214 75.89 68 24.11 0.785 141 50.00 141 50.00 < 0.001 Male (n = 328) 300 91.46 28 8.54 208 63.41 120 36.59 252 76.83 76 23.17 94 28.66 234 71.34 > 50 years (n = 205) 188 91.71 17 8.29 0.696 126 61.46 79 38.54 0.005 154 75.12 51 24.88 0.301 90 43.90 115 56.10 0.146 36 – 50 years (n = 237) 222 93.67 15 6.33 160 67.51 77 32.49 177 74.68 60 25.32 87 36.71 150 63.29 < 36 years (n = 167) 156 93.41 11 6.59 129 77.25 38 22.75 135 80.84 32 19.16 58 34.73 109 65.27 ≥ 9 days (n = 160) 145 90.63 15 9.37 0.181 110 68.75 50 31.25 0.821 135 84.38 25 15.62 0.006 72 45.00 88 55.00 0.050 < 9 days (n = 450) 422 93.78 28 6.22 305 67.78 145 32.22 331 73.56 119 26.44 163 36.22 287 63.78 Among the reported chronic effects, the study results show that females were significantly more likely to report arthralgia (P < 0.001) and edema (P < 0.001) than males. Also, individuals more than 50 years of age were significantly more likely to report chronic arthralgia (P = 0.003) and chronic edema (P = 0.001) than individuals in both younger age groups. Additionally, a significant relationship was observed between a longer duration of the acute phase and both chronic myalgia (P = 0.041) and chronic edema (P = 0.037) (Table 4b).
TABLE 4b.

Proportion distribution of chronic manifestations by sex, age, and acute phase length in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

Variable

Chronic

Arthralgia

P

Headache

P

Myalgia

P

Edema

P

Yes

No

Yes

No

Yes

No

Yes

No

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

No.

%

Total (n = 610)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Female (n = 282)

158

56.03

124

43.97

< 0.001

9

3.19

273

96.81

0.745

24

8.51

258

91.49

0.071

39

13.83

243

86.17

< 0.001

Male (n = 328)

135

41.16

193

58.84

 

9

2.74

319

97.26

 

16

4.88

312

95.12

 

10

3.05

318

96.95

 

> 50 years (n = 205)

110

53.66

95

46.34

0.003

8

3.90

197

96.10

0.540

18

8.78

187

91.22

0.291

28

13.66

177

86.34

0.001

36 – 50 years (n = 237)

121

51.05

116

48.95

 

5

2.11

232

97.89

 

13

5.49

224

94.51

 

13

5.49

224

94.51

 

< 36 years (n = 167)

62

37.13

105

62.87

 

5

2.99

162

97.01

 

9

5.39

158

94.61

 

8

4.79

159

95.21

 

≥ 9 days (n = 160)

87

54.38

73

45.62

0.062

3

1.88

157

98.12

0.349

16

10.00

144

90.00

0.041

19

11.88

141

88.12

0.037

< 9 days (n = 450)

206

45.78

244

54.22

 

15

3.33

435

96.67

 

24

5.33

426

94.67

 

30

6.67

420

93.33

 

Prepared by the authors using study data.

Variable Chronic Arthralgia P Headache P Myalgia P Edema P Yes No Yes No Yes No Yes No No. % No. % No. % No. % No. % No. % No. % No. % Total (n = 610) Female (n = 282) 158 56.03 124 43.97 < 0.001 9 3.19 273 96.81 0.745 24 8.51 258 91.49 0.071 39 13.83 243 86.17 < 0.001 Male (n = 328) 135 41.16 193 58.84 9 2.74 319 97.26 16 4.88 312 95.12 10 3.05 318 96.95 > 50 years (n = 205) 110 53.66 95 46.34 0.003 8 3.90 197 96.10 0.540 18 8.78 187 91.22 0.291 28 13.66 177 86.34 0.001 36 – 50 years (n = 237) 121 51.05 116 48.95 5 2.11 232 97.89 13 5.49 224 94.51 13 5.49 224 94.51 < 36 years (n = 167) 62 37.13 105 62.87 5 2.99 162 97.01 9 5.39 158 94.61 8 4.79 159 95.21 ≥ 9 days (n = 160) 87 54.38 73 45.62 0.062 3 1.88 157 98.12 0.349 16 10.00 144 90.00 0.041 19 11.88 141 88.12 0.037 < 9 days (n = 450) 206 45.78 244 54.22 15 3.33 435 96.67 24 5.33 426 94.67 30 6.67 420 93.33 Prepared by the authors using study data. The results regarding acute effects show that females had a significantly higher (73% vs. 63%) prevalence of headache (PR = 1.16; 95% CI: 1.04 – 1.29) and a significantly higher (50% vs. 29%) prevalence of edema (PR = 1.74; 95% CI: 1.43 – 2.14) than males. Compared to subjects less than 36 years of age, those more than 50 years (PR = 0.80; 95% CI: 0.69 – 0.91) had a significantly lower (61% vs. 77%) prevalence of headache. Those 36 – 50 years of age (PR = 0.87; 95% CI: 0.77 – 0.99) had a significantly lower (68% vs. 77%) prevalence of headache. Moreover, participants with acute phase symptoms of 9 days or greater had a significantly higher (84% vs. 74%) proportion of myalgia (PR = 1.15; 95%CI: 1.04 – 1.26) (Table 4a and Table 5).
TABLE 5.

Association between clinical manifestations and sex, age and acute phase length, in a study of chikungunya at a university in Santo Domingo, the Dominican Republic, 2014

Variable

Acute

Chronic

n

PRa

95%CIb

n

PR

95%CI

n

PR

95%CI

n

PR

95%CI

Total (n = 610)

 

 

 

 

 

 

 

 

 

 

 

 

Sex

Headache

Edema

Arthralgia

Edema

Female (n = 282)

207

1.16

(1.04, 1.29)

141

1.74

(1.43, 2.14)

158

1.36

(1.15, 1.61)

39

4.54

(2.47, 8.33)

Male (n = 328)

208

1.00

 

94

1.00

 

135

1.00

 

10

1.00

 

Age category

Headache

 

 

 

Arthralgia

Edema

> 50 years (n = 205)

126

0.80

(0.69, 0.91)

110

1.45

(1.15, 1.81)

28

2.85

(1.40, 5.83)

36 – 50 years (n = 237)

160

0.87

(0.77, 0.99)

121

1.38

(1.10, 1.72)

13

1.15

(0.49, 2.70)

< 36 years (n = 167)

129

1.00

 

62

1.00

 

8

1.00

 

Acute phase length

Myalgia

 

 

 

Myalgia

Edema

≥ 9 days (n = 160)

135

1.15

(1.04, 1.26)

16

1.97

(1.02, 3.83)

19

1.89

(1.03, 3.47)

< 9 days (n = 450)

331

1.00

 

24

1.00

 

30

1.00

 

PR = prevalence rate ratio.

95% Confidence Interval.

Prepared by the authors using study data.

Variable Acute Chronic n PR 95%CI n PR 95%CI n PR 95%CI n PR 95%CI Total (n = 610) Sex Headache Edema Arthralgia Edema Female (n = 282) 207 1.16 (1.04, 1.29) 141 1.74 (1.43, 2.14) 158 1.36 (1.15, 1.61) 39 4.54 (2.47, 8.33) Male (n = 328) 208 1.00 94 1.00 135 1.00 10 1.00 Age category Headache Arthralgia Edema > 50 years (n = 205) 126 0.80 (0.69, 0.91) 110 1.45 (1.15, 1.81) 28 2.85 (1.40, 5.83) 36 – 50 years (n = 237) 160 0.87 (0.77, 0.99) 121 1.38 (1.10, 1.72) 13 1.15 (0.49, 2.70) < 36 years (n = 167) 129 1.00 62 1.00 8 1.00 Acute phase length Myalgia Myalgia Edema ≥ 9 days (n = 160) 135 1.15 (1.04, 1.26) 16 1.97 (1.02, 3.83) 19 1.89 (1.03, 3.47) < 9 days (n = 450) 331 1.00 24 1.00 30 1.00 PR = prevalence rate ratio. 95% Confidence Interval. Prepared by the authors using study data. Among the reported chronic manifestations, females had a significantly higher (56% vs. 41%) prevalence of chronic arthralgia (PR = 1.36; 95%CI: 1.15 – 1.61) and a significantly higher (14% vs. 3%) prevalence of chronic edema (PR = 4.54; 95%CI: 2.47 – 8.33) than males. In comparison to the subjects less than 36 years of age, those greater than 50 (PR = 1.45; 95%CI: 1.15 – 1.81) had a significantly higher (54% vs. 37%) prevalence of chronic arthralgia and those 36 – 50 years of age (PR = 1.38; 95%CI: 1.10 – 1.72) had a significantly higher (51% vs. 37%) prevalence of chronic arthralgia. Those more than 50 years of age (PR = 2.85, 95%CI: 1.40 – 5.83) also had a significantly higher (14% vs. 5%) prevalence of chronic edema than those less than 36 years. Additionally, participants with acute phase symptoms 9 days or greater had a significantly higher (10% vs. 5%) prevalence of chronic myalgia (PR = 1.97; 95%CI: 1.02 – 3.83) and a significantly higher (12% vs. 7%) prevalence of chronic edema (PR = 1.89; 95%CI: 1.03 – 3.47) (Table 4b and Table 5).

DISCUSSION

Although the 2014 outbreak in the Dominican Republic appears to have ceased, research must be carried out to better understand the prevalence and risk factors of CHIKV infection and its associated clinical manifestations. This study examines the demographics and clinical profile of university personnel reporting CHIKV infection during the recent epidemic. It is our hope that its findings can promote enhanced prevention, diagnosis, and treatment of CHIKV infection, as well as encourage further population-based prevalence studies of CHIKV in the Region. The prevalence of reported CHIKV infection in the study sample appears to reflect that of prior epidemics (19, 23–27). The prevalence was estimated to be 35% and 53% in the 2006 outbreaks in La Reunión (Martinique; 19, 23 – 25) and Kerala (India; 26) respectively. This frequent occurrence of infection is likely reflective of the virus infectivity and pathogenicity, as well as the lack of immunity in the Dominican Republic (due to its recent emergence in the Americas). In participants who reported suspected CHIKV infection, rates of acute clinical manifestations were observed to be comparable to other studies, with some minor differences. As expected, arthralgia and fever were the two most common symptoms (28). This matches the standard case definition, but these symptoms may have been under-reported due to recall bias, especially fever since it tends to be less distinct. The study sample reported myalgia more frequently than the 50% – 60% prevalence reported in various other studies (27, 29). This is a frequently observed symptom after infection with an alphavirus, which has a tropism to muscle cells where it can replicate persistently (6). Additionally, the prevalence of headache was within the typical range (26, 27, 29), while rash was reported at a slightly higher rate than the 40% – 50% prevalence in other studies (12, 26, 27, 30). We also found that a majority of participants who reported infection experienced at least one symptom that persisted beyond the acute phase. While our survey did not specify a particular timeframe for chronic manifestations, the results are comparable to prior CHIKV outbreaks, for which studies reported that 73.6% and 57.0% of subjects had rheumatic symptoms at 1-month and 15-months post-diagnosis, respectively (26, 31). Since chronic manifestations tend to be more common in individuals with comorbidities and concurrent infections, this could potentially explain the slightly lower prevalence of chronic manifestations reported in our sample of university personnel. As expected, arthralgia was by far the most common chronic symptom reported (19, 26–29). The high prevalence of chronic arthralgia can likely be explained by adaptive immune responses that promote the persistence of a high CHIKV viral load in joint-associated tissues (32). Patients with persistent arthralgia have been observed to have higher platelet counts and reduced liver enzyme levels than patients with faster recovery (19). The pathogenesis of joint pain from CHIKV infection is not well understood, but research has pointed towards older age, acute pain severity, and presence of comorbid arthralgia as factors promoting chronicity (31). The high prevalence of chronic arthralgia observed is meaningful due to its reflection of the ongoing disease burden and costs resulting from this large epidemic in Santo Domingo, a major Caribbean city. A recent cohort study in Tolima (Colombia), site of a large outbreak in 2014–2015, found that about half of those with CHIKV infection experienced chronic arthralgia (33). In a smaller cohort study published in a different area of Colombia, the prevalence was even higher. Further research should be conducted in the Dominican Republic and other Latin American countries to determine the impact and timescale of chronic arthralgia among the general population, as well as potential measures to prevent its associated morbidity. Additionally, the study results revealed a significantly higher prevalence of CHIKV infection in females and in younger subjects. The Dirección General de Epidemiología (Directorate General of Epidemiology, Santo Domingo; DIGEPI) reported preliminary case data from the town of San Gregorio de Nigua in March 2014 (34). This data showed a similar proportion of CHIKV infection in females and males, and a peak prevalence in adolescents 15 – 19 years of age. The higher proportion of CHIKV infection observed in females and younger subjects in our study may be linked to increased outdoor exposures. This may be an important finding and demonstrate differences in symptomatic illness among population groups in the Dominican Republic. Alternatively, the finding could be linked to recall bias or inaccurate diagnosis. More research into the demographic variability between outbreaks could provide valuable information. Finally, in our bivariate analyses, chronic arthralgia and chronic edema were significantly related to female sex and older age. We also observed a significantly higher prevalence of chronic edema and chronic myalgia in those who reported a longer phase of acute symptoms. These findings mirror the results of two retrospective studies following the Reunion Island outbreak (19, 31), which reported that patients with persistent arthralgia or rheumatic symptoms had a higher mean age and were more likely to be female. These studies serve as a valuable point of comparison, but had much smaller sample sizes (56 and 84 patients with persistent rheumatic symptoms, respectively). The aforementioned study in Colombia also found a higher prevalence of chronic arthralgia in females and older individuals (33). A potential explanation for the increased prevalence of symptoms in females is the tendency to have higher rates of headaches, edema, and joint or muscle pain during pregnancy or post-menopause (35). It could also be linked to differences in age between the male and female participants; we found that females in our study were younger [not reported]. The principal strength of our study was the large sample size of 1 236 individuals. Sampling from a large public university population is likely to promote greater generalizability of the findings due to the representative nature of this population. Post-outbreak studies to observe infection and clinical manifestation prevalence in the Dominican Republic and the Americas, as well as risk factors related to poorer outcomes, have not been sufficiently studied to date. This study also investigated reported chronic manifestations, which have been largely unexplored in the CHIKV epidemic in the Americas, and identified factors linked to increased prevalence.

Limitations

Even after taking into account the methodological criteria applied in the design stage, the results described above should be analyzed carefully, while keeping in mind the study limitations. Similar to most studies of CHIKV infection, past and current symptoms were self-reported without laboratory confirmation, which may have led to over-or under-estimation of the symptom prevalence. The survey was also carried out months after infection in most cases, which could have promoted recall bias and magnification of the symptoms. In Tables 4 and 5, it is also clear that the significance of the results was affected by the sample size in each category. For example, the rarity of chronic headaches made it more difficult for a significant relationship to be observed. Additionally, the surveys would have been more informative if they contained supplementary questions on factors such as socioeconomic status, educational level, recent pregnancy, and concurrent illness. Inclusion of university students in the analysis would also have provided additional information.

Conclusions

To the authors’ knowledge, this is the first population-based CHIKV infection prevalence study in the Dominican Republic, and the first to explore the prevalence of the clinical manifestations of CHIKV infection in university professors and staff. We observed a high prevalence of CHIKV infection and chronic arthralgia, as well as various significant relationships among key risk factors and clinical manifestations of CHIKV infection. After comparisons were performed, we observed that our findings generally mirror the results of studies from other outbreaks, such as that of Reunion Island. This research is important in highlighting the impact of CHIKV infection on the Caribbean and the Region of the Americas as a whole, and allowing for improved characterization of resulting clinical manifestations. Additional longitudinal research and population-based prevalence studies could provide further insight into these effects.

Acknowledgements.

The researchers acknowledge the Facultad de Ciencias de Salud (School of Health Sciences) at the Universidad Autónoma de Santo Domingo for administrative support, as well as the Columbia University Mailman School of Public Health and its affiliated IFAP Global Health Program (New York, NY) for travel support. We would also like thank the numerous students who conducted the surveys and assisted with initial data collection, as well as all the professors and staff who participated.

Disclaimer.

Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or PAHO.
  25 in total

1.  Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 French cases.

Authors:  Sophie Larrieu; Nicolas Pouderoux; Thierry Pistone; Laurent Filleul; Marie-Catherine Receveur; Daouda Sissoko; Khaled Ezzedine; Denis Malvy
Journal:  J Clin Virol       Date:  2009-12-08       Impact factor: 3.168

2.  Unexplained swelling symptoms in women (idiopathic oedema) comprise one component of a common polysymptomatic syndrome.

Authors:  M G Dunnigan; J B Henderson; D Hole; A J Pelosi
Journal:  QJM       Date:  2004-11

3.  Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients.

Authors:  Gianandrea Borgherini; Patrice Poubeau; Frederik Staikowsky; Manuella Lory; Nathalie Le Moullec; Jean Philippe Becquart; Catherine Wengling; Alain Michault; Fabrice Paganin
Journal:  Clin Infect Dis       Date:  2007-04-18       Impact factor: 9.079

4.  Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor.

Authors:  Angela Chow; Zhisheng Her; Edward K S Ong; Jin-miao Chen; Frederico Dimatatac; Dyan J C Kwek; Timothy Barkham; Henry Yang; Laurent Rénia; Yee-Sin Leo; Lisa F P Ng
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

5.  A report of 21 cases of rheumatoid arthritis following Chikungunya fever. A mean follow-up of two years.

Authors:  Eric Bouquillard; Bernard Combe
Journal:  Joint Bone Spine       Date:  2009-12       Impact factor: 4.929

6.  Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island.

Authors:  Gianandrea Borgherini; Patrice Poubeau; Annie Jossaume; Arnaud Gouix; Liliane Cotte; Alain Michault; Claude Arvin-Berod; Fabrice Paganin
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

Review 7.  Chikungunya, an epidemic arbovirosis.

Authors:  Gilles Pialoux; Bernard-Alex Gaüzère; Stéphane Jauréguiberry; Michel Strobel
Journal:  Lancet Infect Dis       Date:  2007-05       Impact factor: 25.071

8.  Chikungunya virus infection.

Authors:  Fabrice Simon; Emilie Javelle; Manuela Oliver; Isabelle Leparc-Goffart; Catherine Marimoutou
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

9.  Prospective study of Chikungunya virus acute infection in the Island of La Réunion during the 2005-2006 outbreak.

Authors:  Frederik Staikowsky; François Talarmin; Philippe Grivard; Abdel Souab; Isabelle Schuffenecker; Karin Le Roux; Marc Lecuit; Alain Michault
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

10.  Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period.

Authors:  Daouda Sissoko; Denis Malvy; Khaled Ezzedine; Philippe Renault; Frederic Moscetti; Martine Ledrans; Vincent Pierre
Journal:  PLoS Negl Trop Dis       Date:  2009-03-10
View more
  3 in total

1.  Asynchronicity of endemic and emerging mosquito-borne disease outbreaks in the Dominican Republic.

Authors:  Mary E Petrone; Rebecca Earnest; José Lourenço; Moritz U G Kraemer; Robert Paulino-Ramirez; Nathan D Grubaugh; Leandro Tapia
Journal:  Nat Commun       Date:  2021-01-08       Impact factor: 14.919

2.  Molecular and Clinical Characterization of Chikungunya Virus Infections in Southeast Mexico.

Authors:  Kame A Galán-Huerta; Erik Martínez-Landeros; Juan L Delgado-Gallegos; Sandra Caballero-Sosa; Iliana R Malo-García; Ildefonso Fernández-Salas; Javier Ramos-Jiménez; Ana M Rivas-Estilla
Journal:  Viruses       Date:  2018-05-09       Impact factor: 5.048

3.  Evidence of Chikungunya Virus Disease in Pakistan Since 2015 With Patients Demonstrating Involvement of the Central Nervous System.

Authors:  Kelli L Barr; Erum Khan; Joveria Q Farooqi; Kehkashan Imtiaz; Dhani Prakoso; Faisal Malik; John A Lednicky; Maureen T Long
Journal:  Front Public Health       Date:  2018-07-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.